Vogenx, Inc. (VOGX)
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Vogenx Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 14.86M shares outstanding
USVogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis.
The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Leadership
James Green
President, CEO & Chairman
William Wilkison
Chief Scientific Officer, Chair of Scientific Advisory Board & Director
Steven R. Delmar
CFO, Corporate Secretary & Director
Employees
4
Country
US
Sector
Healthcare
Website
vogenx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 DELMAR STEVEN R | Chief Financial Officer | Grant/Award | 155.0K | -- | Oct 2, 2026 |
 Boris Timothy | Director | Grant/Award | 50.0K | -- | Oct 2, 2026 |
 Wilkison William | Chief Scientific Officer | Grant/Award | 155.0K | -- | Oct 2, 2026 |
 Toombs Kenneth John | Director | Grant/Award | 50.0K | -- | Oct 2, 2026 |
 Pieraccini Peter | Director | Grant/Award | 50.0K | -- | Oct 2, 2026 |
 Green James | Chief Executive Officer | Grant/Award | 155.0K | -- | Oct 2, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
JANUS HENDERSON GROUP Ltd. · may incl. warrants· filed Sep 2026 | 1.9M | 12.9% | 13G |
 DELMAR STEVEN R Chief Financial Officer, Director | 704.3K | 4.7% | FORM 4 |
Insiders
- DELMAR STEVEN RChief Financial Officer
- Boris TimothyDirector
- Wilkison WilliamChief Scientific Officer
- Toombs Kenneth JohnDirector
- Pieraccini PeterDirector
- Green JamesChief Executive Officer
based on 14.86M shares outstanding
US30d Avg
100.22K
60d Avg
125.33K
90d Avg
166.59K